Journey to the Center of the Vape – Part 1

Sep 26, 2019 | Blogs, Food / Beverage | 0 comments

The safety of vaping has recently become a topic of concern. The public wants answers about the safety of these products. Health authorities are scrambling to find the cause of the mysterious vaping illness that has been seen in hundreds of cases across the U.S., and that has caused multiple deaths.

Current news highlights related to recent cases:

There have been 11 vaping-related confirmed deaths as of Sept 26
The U.S Center for Disease Control and Prevention (CDC) reported vaping-related illness had sickened 530 people but NBC News reports there are more than 1000 cases of the illness being investigated across the U.S
The Trump Administration plans to ban flavored e-cigarettes
This week, the state of Massachusetts became the first state to temporarily ban the sale of all vaping products and devices. This follows the flavored e-cigarettes ban last week by New York and Michigan state
Hawaii has banned unregulated cannabidiol (CBD) products
India has completely banned e-cigarettes
U.S. Food and Drug Administration (FDA) identified vitamin E acetate as a common contaminant in marijuana vaping product used by many of the sick patients
The vaping illness outbreak has affected both cannabis and nicotine products
The world’s largest retailer, Walmart, will stop selling e-cigarettes

Vaping has been around for years. It is too soon to know whether the recent cases are a new type of outbreak or something common that is just being seen through a lens of heightened awareness. The question remains: What is causing this illness?

Is investigating vitamin E acetate or polyethylene glycol the right focus? What about the questions surrounding the use of tetrahydrocannabinol (THC) as an ingredient in these e-cigarettes? Is mixing THC and nicotine to blame? The search for answers continues.

It makes sense to look at how an outbreak like this could happen. How could something unsafe make it into vaping products? One possible contributor to the situation is the lack of regulations around ingredients in both tobacco and cannabis vaping products. There is little transparency around ingredient labeling and few restrictions on additives. In an effort to further protect children, the FDA has announced plans to ban all non-tobacco e-cigarettes.

Another piece of the puzzle is the increase in counterfeit and illegal vaping products that have infected the market. Products are tampered with and adulterated, without consideration for the user’s safety. For instance, Wisconsin police reported a drug operation that was filling 3000-5000 illegal THC-infused vape cartridges a day for 2 years! Also, extremely concerning is that the THC potency of these products was 157 times higher than indicated on the labels. Imagine someone purchasing a vape pen from what they assume is a safe and reputable vendor (who follows strict testing protocols) only to find that it’s laced with synthetic cannabinoids, or worse, fentanyl.

Other states may soon follow Hawaii’s lead in regulating CBD products, now that the risk of vaping illness is very real. This might also impact CBD-infused drinks found on shelves in established institutions—due to a lack of testing to demonstrate product safety. It will be interesting to see how regulations evolve. Will the rest of the world follow India and ban e-cigarettes entirely, too?

As analytical scientists, we want to understand what about the vaping chemistry is causing injury. Is it a single toxic compound, or a mixture of substances? Is there a mechanism or trace-level compound that we’re not examining?

Stay tuned for part 2 of this piece where we discuss vaping chemistry and share what we found when we tested several commercial vape products.

As of the writing of this article, these were the most up to date facts and figures.

Pharma perspectives: The role of digital and software solutions in pharmaceutical R&D

It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.

Application of CGE in cell and gene therapy

In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.

From exposure to discovery: How SWATH DIA can enhance our understanding of the exposome and its impact on health

Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.

Posted by

Paul Winkler

I play an active role in supporting cannabis (marijuana and hemp) applications at SCIEX. I have more than 30 years of experience owning and operating contract labs in the environmental and bioanalytical markets. I've been part of the SCIEX family since 2011. I started as a field application chemist, and today I'm a market development manager for the North America team. Helping customers like you with your analytical challenges and educating the market on the many possibilities of LC-MS/MS systems, is my passion.

0 Comments